Regulatory Filings • Dec 14, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
_________ false
C003������� �� ��� ��"�2PublicBIOLINE RX LTD9253Corporation no: 513398750Stock Exchange/Market: NASDAQ CM2271381HaMa'ayan 2 , Modi'in 7177871 , , IsraelTel: 08-6429100 , Fax: 08-6429101E.mail address: [email protected] via MAGNA: 14/12/2015 Time of broadcast: 13:49 13:43:38
| Company site: | www.biolinerx.com |
Reference: 2015-02-179313
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.
| Attached hereto is a report on | BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment |
6-K_BL8040_141215_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| Previous names of reporting entity: |
| Date of revision of form structure: 04/11/2015 |
| - - - |
| Name of the Signatory: : Kotler Norman Harold , Position of Signatory in the reporting corporation: General Counsel & Company Secretary , Name of Employer Company: . |
| Hartum Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: [email protected] 1 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.